Ironwood Pharmaceuticals, Inc. (IRWD)

Ironwood Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	317.68	351.41	442.74	410.6	413.75	389.52
Revenue Growth (YoY)	-23.18%	-20.63%	7.83%	-0.76%	6.22%	-9.08%
Cost of Revenue	9.17	7.55	6.15	4.94	70.41	91.2
Gross Profit	308.51	343.86	436.59	405.66	343.35	298.33
Selling, General & Admin	130.93	144.27	142.11	115.99	111.13	140
Research & Development	103.87	103.87	98.64	39.33	-	-
Operating Expenses	234.8	248.14	240.75	155.32	111.13	140
Operating Income	73.71	95.72	195.84	250.34	232.22	158.32
Interest Expense	-34.12	-33.29	-21.38	-7.6	-31.15	-29.48
Interest & Investment Income	4.17	4.47	18.97	9.5	0.73	1.5
Other Non Operating Income (Expenses)	0.93	0.89	-0.23	0.18	-1.18	-6.11
EBT Excluding Unusual Items	44.68	67.79	193.2	252.42	200.61	124.24
Merger & Restructuring Charges	-20.72	-2.59	-45.82	-	0.04	-15.38
Pretax Income	23.97	65.2	-948.07	252.42	200.66	108.86
Income Tax Expense	56.31	64.32	83.49	77.36	-327.79	2.69
Earnings From Continuing Operations	-32.34	0.88	-1,032	175.07	528.45	106.18
Net Income to Company	-32.34	0.88	-1,032	175.07	528.45	106.18
Minority Interest in Earnings	-	-	29.32	-	-	-
Net Income	-32.34	0.88	-1,002	175.07	528.45	106.18
Net Income to Common	-32.34	0.88	-1,002	175.07	528.45	106.18
Net Income Growth	-	-	-	-66.87%	397.71%	393.73%
Shares Outstanding (Basic)	160	159	155	154	162	159
Shares Outstanding (Diluted)	160	160	155	186	164	161
Shares Change (YoY)	2.34%	2.99%	-16.57%	13.32%	2.34%	2.97%
EPS (Basic)	-0.20	0.01	-6.45	1.13	3.26	0.67
EPS (Diluted)	-0.20	0.01	-6.45	0.96	3.21	0.66
EPS Growth	-	-	-	-69.98%	386.36%	378.84%
Free Cash Flow	78.41	103.41	183.15	273.63	261.63	166.99
Free Cash Flow Per Share	0.49	0.65	1.18	1.47	1.59	1.04
Gross Margin	97.11%	97.85%	98.61%	98.80%	82.98%	76.59%
Operating Margin	23.20%	27.24%	44.23%	60.97%	56.12%	40.64%
Profit Margin	-10.18%	0.25%	-226.37%	42.64%	127.72%	27.26%
Free Cash Flow Margin	24.68%	29.43%	41.37%	66.64%	63.23%	42.87%
EBITDA	75.69	97.73	197.41	251.76	233.74	160.69
EBITDA Margin	23.83%	27.81%	44.59%	61.31%	56.49%	41.25%
D&A For EBITDA	1.98	2.01	1.58	1.42	1.52	2.36
EBIT	73.71	95.72	195.84	250.34	232.22	158.32
EBIT Margin	23.20%	27.24%	44.23%	60.97%	56.12%	40.64%
Effective Tax Rate	234.95%	98.65%	-	30.65%	-	2.47%
Revenue as Reported	317.68	351.41	442.74	410.6	413.75	389.52

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q